Full-Time

Aseptic Technician 1

Deadline 8/24/26
Zoetis Services

Zoetis Services

10,001+ employees

Develops, manufactures, and sells animal vaccines

No salary listed

H1B Sponsorship Available

Charles City, IA, USA

In Person

Saturday through Monday, 5:00 AM to 5:30 PM.

Category
Biology & Biotech (1)
Required Skills
Inventory Management
GMP

Get referred to Zoetis Services

See people who can refer or advise you

Requirements
  • A high school education or GED is required.
  • Demonstrated teamwork and collaboration skills are required.
  • Strong communication skills are required.
  • The employee must be able to sit, stand, and walk for long periods of time.
  • The employee must be able to wear a respirator.
  • The employee must be able to reach above shoulder level, bend or stoop, push or pull, and handle or grip frequently.
  • The employee must be able to work scheduled 40 hours and overtime as needed.
  • The employee must be comfortable working in varying temperatures.
  • The employee must be able to don proper personal protective equipment, including a Tyvek gown.
  • The employee must frequently lift and carry 5 to 25 pounds.
  • The employee must regularly reach, bend, stoop, and twist.
  • The employee must perform repetitive motion and substantial movement of the wrists, hands, and fingers.
  • All applicants must possess or obtain authorization to work in the United States for Zoetis.
Responsibilities
  • Execute aseptic techniques and clean room procedures or support-area procedures in a good manufacturing practice facility.
  • Maintain appropriate departmental current good manufacturing practice documentation.
  • Execute all written procedures, including batch records and standard operating procedures.
  • Follow and comply with all financial procedures.
  • Follow and comply with all site safety procedures.
  • Operate departmental equipment, including setup and takedown.
  • Work effectively in a team environment and communicate with multiple departments.
  • Follow good manufacturing practices.
  • Perform clean room gowning.
  • Perform aseptic processing while working in a clean room setting.
  • Maintain accurate inventory.
  • Follow manufacturing directions.
  • Prepare cell cultures, infect cells, harvest cells, blend vaccine serials, and fill vaccine serials.
Desired Qualifications
  • Post-high-school education in the sciences or other related disciplines is preferred.
  • Good mathematical, science, and computer skills are preferred.

Zoetis creates medicines and vaccines to protect the health of companion animals and livestock. Its products include vaccines, anti-infectives, parasiticides, dermatology and other therapeutics, medicated feed additives, and diagnostics, sold through veterinarians, livestock producers, and pet owners. The company reaches customers in more than 100 countries and relies on big R&D and a global marketing network to bring new solutions to market. Its goal is to improve animal health worldwide by delivering science-based products and services that help care for animals and prevent disease.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parsippany-Troy Hills, New Jersey

Founded

1952

Get referred to Zoetis Services

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Portela in Canada and the EU expands Zoetis' chronic-pain franchise beyond Solensia.
  • International revenue rose 6% in Q2 2026, offsetting U.S. companion-animal softness.
  • Livestock revenue rose 11% in Q2 2026, and diagnostics grew 12% despite market weakness.

What critics are saying

  • Zoetis cut 2026 revenue guidance to $9.12-$9.32 billion after Q2 2026 weakness.
  • U.S. companion-animal revenue fell 7% in Q2 2026 as Elanco and Merck pressured pricing.
  • If clinic visits stay weak through 2027, Zoetis loses share and valuation rerates lower.

What makes Zoetis Services unique

  • Zoetis launched Portela in July 2026, first three-month feline osteoarthritis antibody.
  • Zoetis owns broad global animal-health scale across 100 countries and two resilient end markets.
  • Zoetis combines veterinary science, biologics, and manufacturing control under Jay Saccaro since August 17.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

15%

1 year growth

15%

2 year growth

15%
Yahoo Finance
Aug 18th, 2026
Zoetis drops 40% in 2025 as Michael Burry bets on beaten-down animal health stock

Zoetis, an animal health company, has drawn attention from investor Michael Burry, who is long the stock according to Substack disclosures cited by media outlets. The shares have fallen roughly 40% this year and over 70% from their 2021 peak. Competition from Elanco and Merck in dermatology and parasite treatments has pressured results. In fiscal Q2 2026, revenue was roughly flat, with US sales down 7% whilst international revenue grew 6%. The stock now trades near 12 times forward earnings, compared with a historical average of 30 times. Zoetis maintains around 86% of the US pet skin drug market, with gross margins above 70%. Wall Street analysts remain mostly bullish, with consensus price targets suggesting roughly 70% upside potential.

Yahoo Finance
Aug 15th, 2026
Zoetis misses Q2 revenue target, slashes full-year guidance by 6.1% amid vet visit decline

Zoetis reported flat revenue of $2.47 billion in Q2, missing Wall Street estimates of $2.50 billion, though adjusted earnings per share of $1.87 slightly beat consensus. The animal health company faces intensifying competition in key Companion Animal categories and declining US veterinary clinic visits. CEO Kristin Peck noted that veterinary visits have declined across markets for multiple years, coinciding with price increases exceeding broader consumer inflation. The company's Livestock and Diagnostics segments showed resilience despite weakness in dermatology and parasiticides. Zoetis lowered its full-year revenue guidance to $9.22 billion from $9.82 billion, a 6.1% reduction, and cut adjusted EPS guidance to $6.20, down 10.5%. Operating margin fell to 37.4% from 39.1% year-on-year. Management indicated it is implementing temporary, targeted promotional actions rather than permanent price cuts to defend market share. Competitive pressures may persist into 2027.

Yahoo Finance
Aug 7th, 2026
Zoetis appoints GE Healthcare CFO Jay Saccaro as dual finance chief and COO

Zoetis has appointed former GE Healthcare CFO Jay Saccaro to a newly created dual role as CFO and chief operating officer, effective 17 August. Saccaro, who spent three years at GE Healthcare and nine years as CFO at Baxter International Healthcare, will receive an annual base salary of $1 million, with eligibility for bonuses totalling 100% of his salary and long-term incentives worth $5 million. He will also receive a one-time restricted stock unit award valued at approximately $6.2 million and a cash award of $1.2 million. Current CFO Wetteny Joseph will transition to special advisor on 16 August, remaining in a non-executive role until February 2027 or an earlier agreed date. The appointment comes as the New Jersey-based animal health company seeks new growth opportunities amid economic headwinds.

Yahoo Finance
Aug 7th, 2026
Zoetis Q2 earnings beat at $1.87 per share, revenues flat at $2.47B, 2026 outlook cut

Zoetis reported second-quarter 2026 adjusted earnings of $1.87 per share, beating the consensus estimate of $1.84. However, total revenues of $2.47 billion fell flat year over year and marginally missed expectations of $2.49 billion. US segment revenues declined 7% to $1.30 billion, driven by an 11% drop in companion animal product sales due to softer demand and increased competition. Livestock product sales in the US rose 23% to $222 million. International segment revenues increased 8% to $1.17 billion, supported by growth in parasiticides and livestock products. Zoetis cut its 2026 revenue guidance to $9.12-9.32 billion, reflecting expected operational growth of negative 1-3%. Year to date, shares have plunged 40%.

Yahoo Finance
Aug 6th, 2026
Zoetis revenue falls to $2.5B amid 6% drop in companion animal sales, livestock up 11%

Zoetis reported Q2 2026 revenue of $2.5 billion, flat year-over-year and down 1% on an organic operational basis. Adjusted diluted earnings per share rose 4% to $1.87, whilst adjusted net income fell 2% to $781 million. The animal health company's global companion animal revenue declined 6% to $1.7 billion, with key dermatology products down 16% to $395 million. However, livestock revenue grew 11% to $731 million, driven by demand in cattle and poultry. International markets provided growth momentum, with revenue up 6% to $1.2 billion, whilst US revenue fell 7% to $1.3 billion. Companion animal diagnostics revenue increased 12% to $118 million. For full-year 2026, Zoetis expects revenue of $9.12 billion to $9.32 billion and adjusted diluted EPS of $6.15 to $6.25.